A Pipeline of Precision Therapeutics



A QUANTUM CHANGE

Mirati is developing a pipeline of drug candidates targeting genetic and epigenetic drivers of cancer. Each program is based on a scientific rationale to identify and treat patients most likely to respond to Mirati’s targeted therapies. This includes the use of companion diagnostic assays that detect mutations of specific cancer genes.

16-MIR-103-trifold-C9-8.5x15.indd